Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18039295 | 1.00 | EPHX1 (0.38) | EPHX1ALDH1A1CYP3A4ALOX15TDP1 | |
| SCHEMBL13896957 | 0.99 | ALDH1A1 (0.38) | EPHX1ALDH1A1CYP3A4ALOX15TDP1 | |
| SCHEMBL1404280 | 0.86 | ALDH1A1 (0.37) | ALDH1A1CYP3A4ALOX15TDP1 | |
| SCHEMBL3857103 | 0.83 | ALDH1A1 (0.33) | ALDH1A1CYP3A4ALOX15TDP1 | |
| SCHEMBL6829962 | 0.81 | EPHX1 (0.42) | EPHX1ALDH1A1CYP3A4ALOX15TDP1 | |
| SCHEMBL30118443 | 0.81 | ALDH1A1 (0.38) | EPHX1ALDH1A1CYP3A4ALOX15TDP1 | |
| SCHEMBL12484222 | 0.81 | EPHX1 (0.42) | EPHX1ALDH1A1CYP3A4ALOX15TDP1 | |
| SCHEMBL11032438 | 0.80 | ALDH1A1 (0.40) | ALDH1A1CYP3A4ALOX15TDP1 | |
| SCHEMBL12661192 | 0.78 | LMNA (0.41) | ALDH1A1CYP3A4ALOX15TDP1 | |
| SCHEMBL14046750 | 0.76 | ALDH1A1 (0.34) | ALDH1A1CYP3A4ALOX15TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935669-B2 | Compounds for a controlled release of active molecules | FIRMENICH SA (CH) | 2011-05-03 | — | — | US | disclosed |
| US-7935669-B2 | Compounds for a controlled release of active molecules | FIRMENICH SA (CH) | 2011-05-03 | — | — | US | disclosed |
| US-7723286-B2 | Compounds for a controlled release of active molecules | FIRMENICH SA (CH) | 2010-05-25 | — | — | US | disclosed |
| US-7723286-B2 | Compounds for a controlled release of active molecules | FIRMENICH SA (CH) | 2010-05-25 | — | — | US | disclosed |
| US-20090181878-A1 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH SA | 2009-07-16 | — | — | US | disclosed |
| US-20090181878-A1 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH SA | 2009-07-16 | — | — | US | disclosed |
| US-20040220074-A1 | Compounds for a controlled release of active molecules | FIRMENICH SA (CH) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220074-A1 | Compounds for a controlled release of active molecules | ACLY, PTGES, NOTUM | EPHX1 306/4885ALDH1A1 355/4885CYP3A4 199/4885 |
| US-20090181878-A1 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | ACLY, PTGES, PPOX | EPHX1 298/4885ALDH1A1 315/4885CYP3A4 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.